First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT – Get Free Report) shares were up 1% during mid-day trading on Monday . The company traded as high as GBX 1,698.30 ($21.85) and last traded at GBX 1,698.30 ($21.85). Approximately 316 shares changed hands during trading, a decline of 82% from the average daily volume of 1,770 shares. The stock had previously closed at GBX 1,680.80 ($21.63).
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Stock Up 1.0 %
The company has a current ratio of 9.42, a quick ratio of 9.27 and a debt-to-equity ratio of 0.04. The business has a 50-day moving average price of GBX 1,589.06 and a 200-day moving average price of GBX 1,528.03. The firm has a market cap of £5.02 billion and a P/E ratio of -1,543.91.
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Company Profile
Forbidden Technologies plc develops and owns cloud-based video technology in the United Kingdom, North America, and internationally. It offers Forscene, a cloud based video post-production and publishing platform with various applications, such as editing, adding closed caption, graphics, metadata fast, remote viewing, collaboration, and publishing content.
Further Reading
- Five stocks we like better than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion
- The 3 Best Retail Stocks to Shop for in August
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- Russell 2000 Index, How Investors Use it For Profitable Trading
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
Receive News & Ratings for First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation and related companies with MarketBeat.com's FREE daily email newsletter.